Three Years After US Filing, Biocon’s Bevacizumab Remains Out Of Reach
Indian Firm Has Received CRL From FDA, Must Resolve Facility Observations
Following launches in other key developed markets, Biocon’s plans to break into the US bevacizumab market continue to be frustrated, with further bad news from the US Food and Drug Administration.
